QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Q1 Milestones for Subsidiary — Notes Corrected Information
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on psychedelic pharmaceutical therapies, has noted key achievements reached by its wholly owned subsidiary Adelia Therapeutics Inc. Most notably, Adelia has achieved key milestones outlined in the terms of a contribution agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and previous Adelia shareholders. Those milestones are for Year 1 Q3 (i)-(iii) and Year 1 Q4 (i) and (iii), as contemplated by the terms of the Dec. 7, 2020, agreement. Consequently, the company announced that, in accordance with the agreement, Class B common shares will be issued to Adelia shareholders…